The DOI matches its Crossref record.
Lower urinary tract symptoms, pain and quality of life assessment in chronic non-bacterial prostatitis patients treated with α-blocking agent doxazosin; versus placebo
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In all, 10 placebo‐controlled RCTs (n = 58–272) were identified that evaluated α‐adrenergic antagonists (tamsulosin 53, 54, 55, alfuzosin 56, 57, doxazosin 58, 59, terazosin 60, 61 and silodosin 62) in CBP and CP/CPPS.”
From Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline (2015) · cites this paper as [58]
In the citing paper
“Most (eight) showed positive results, with significant differences vs placebo in NIH‐CPSI total, urinary symptom, pain, and/or QoL scores 54, 55, 56, 57, 59, 60, or in scores using other validated symptom scoring tools 58, 61.”
From Diagnosis and treatment of chronic bacterial prostatitis and chronic prostatitis/chronic pelvic pain syndrome: a consensus guideline (2015) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 22
- Barry MJ, Fowler FJ Jr, O'Leary MP et al. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 1992; 148: 1549–1557. · DOI · Paper page
- Cockett ATK, Aso Y, Denis L et al. Recommendations of the International Consensus Committee concerning: (1) Prostate symptom score (I-PSS) and quality of life assessment. (2) Diagnostic work-up of patients presenting with symptoms suggestive of prostatism. (3) Standardization of the evaluation of treatment modalities. (4) BPH treatment recommendations. In: Cockett ATK, Khoury S, Aso Y et al., eds. The 2nd International Consultation on Benign Prostatic Hyperplasia (BPH). Channel Islands: Scientific Communication International Ltd., 1993: 553–564.
- Neal DE Jr, Moon TD. Clinical trials of terazosin in non-bacterial prostatitis. J Urol (Part 2) 1992; 147: 231A (abstract 72).
- Meares EM, Stamey TA. Bacteriologic localization patterns in bacterial prostatitis and urethritis. Invest Urol 1968; 5: 492–518.
- Lepor H and Machi G. Comparison of AUA symptom index in unselected males and females between fifty-five and seventy-nine years of age. Urology 1993; 42: 36–40. · DOI
- Kojima M, Naya Y, Inoue W et al. The American Urological Association symptom index for Benign Prostatic Hyperplasia as a function of age volume and ultrasonic appearance of the prostate. J Urol 1997; 157: 2160–2165. · doi:10.1016/s0022-5347(01)64702-5
- Marks LS, Partin AW, Gormley GJ et al. Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia. J Urol 1997; 157: 2171–2178. · DOI
- Kaplan SA, Te AE, Jacobs BZ. Urodynamic evidence of vesical neck obstruction in men with misdiagnosed chronic non-bacterial prostatitis and the therapeutic role of endoscopic incision of the bladder neck. J Urol 1994; 152: 2063–2065. · doi:10.1016/s0022-5347(17)32309-1
- Kaplan SA, Santarosa RP, D'Alisera PM et al. Pseudo-dyssynergia (contraction of the external sphincter during voiding) misdiagnosed as chronic non-bacterial prostatitis and the role of biofeedback as a therapeutic option. J Urol 1997; 157: 2234–2237. · DOI
- Young RA, Brogden RN. Doxazosin: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy mild to moderate hypertension. Drugs 1988; 35: 525–541. · doi:10.2165/00003495-198835050-00003
- Fawzy A, Braun K, Lewis GP et al. Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J Urol 1995; 154: 105–109. · doi:10.1016/s0022-5347(01)67240-9
- Kirby RS, Chapple CR, Christmas TJ. Doxazosin minimal blood pressure effects in normotensive BPH patients. J Urol (Part 2) 1993; 149: 434A (abstract 886).
- Shapiro E, Hartanto V, Lepor H. Anti-desmin vs anti-actin for quantifying the area density of prostate smooth muscle. Prostate 1992; 20: 259–267. · doi:10.1002/pros.2990200402
- Tsujii T, Azuma H, Yamaguchi T, Oshima H. A possible role of decreased relaxation mediated by α-adrenoceptors in bladder outlet obstruction by benign prostatic hyperplasia. Br J. Pharmacol 1992; 107: 803–807. · doi:10.1111/j.1476-5381.1992.tb14527.x
- Kirby RS. Efficacy of doxazosin in normotensive and hypertensive patients with benign prostatic hyperplasia. Scand J Urol Nephrol Suppl 1995; 168: 29–33.
- Lepor H, Kaplan SA, Klimberg I et al. Doxazosin for benign prostatic hyperplasia: long term efficacy and safety in hypertensive and normotensive patients. J Urol 1997; 157: 525–530. · doi:10.1016/s0022-5347(01)65193-0
- Barbalias GA, Nikiforidis G, Liatsikos EN. α-Blockers for the treatment of chronic prostatitis in combination with anti-biotics. J Urol 1998; 159: 883–887. · doi:10.1016/s0022-5347(01)63761-3
- Meares EM Jr. Prostatodynia: clinical findings and rationale for treatment. In: Weidner W, Brunner H, Krause W, Rothauge CF, eds. Therapy of Prostatitis. San Francisco: W. Zuckschwerdt Verlag, 1986; (11): 207–212.
- Barbalias GA. Prostatodynia or painful male urethral syndrome? Urology 1990; 36: 146–153. · doi:10.1016/0090-4295(90)80214-8
- Lowentritt JE, Kawahara K, Human LG et al. Bacterial infection in prostatodynia. J Urol 1995; 154: 1378–1381. · doi:10.1016/s0022-5347(01)66870-8
- Shafik A. Pudental canal syndrome: a new etiological factor in prostatodynia and its treatment by pudental decompression. Pain Dig 1998; 8: 32–38.
- Neal DE, Moon TD. Use of terazosin in prostatodynia and validation of a symptom score questionnaire. Urology 1994; 43: 460–465. · doi:10.1016/0090-4295(94)90231-3
Cited by
Rees, J., Abrahams, M., Doble, A., Cooper, A., & the Prostatitis Expert Reference Group (PERG) (2015) · BJU International · doi:10.1111/bju.13101 · Cited by 371
Metadata
- Authors
- Evliyaoğlu, Y., & Burgut, R.
- Venue
- International Urology and Nephrology
- Published
- 2002-09
- Volume
- 34
- Issue
- 3
- Pages
- 351-356
- ISSN
- 0301-1623
- 1573-2584
- Cited by
- 33
- References
- 0
- Language
- en
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.